First-in-class drugs preventing cancer immune evasion.
iOmx Therapeutics focuses on the development of next-generation, first-in-class cancer immune-checkpoint inhibitors. By systematically screening human tumor cells, the Company has identified a number of novel targets and is building a pipeline of drug candidates against them.
The Company was founded on the successful concept of cancer immune-checkpoint therapy, which works by breaking down the inherent resistance mechanisms of tumors against immune attack. Reactivating the host immune response by neutralizing these negative interactions is the key idea behind cancer immune-checkpoint therapy.
The clinical successes of anti-CTLA-4 and anti-PD1/PD-L1 immune-checkpoint inhibitors have been transformative in certain tumor indications. However, as promising as they are to date, they do not benefit a large proportion of patients and are only regarded as the beginning of cancer immunotherapy.
iOmx’s founders have developed a systematic, high-throughput genetic screening approach, called iOTarg, that allows the comprehensive identification of checkpoint molecules, i.e. ligands on human cancer cells that inhibit T cell-mediated tumor cell killing. To date, this screening technology has been applied to tumor cells derived from multiple tumor entities and is continuously expanding. Several novel targets have been identified and validated, using clinical tumor samples and tumor-infiltrating lymphocytes (TILs). Many of them exhibit stronger inhibition of T cell killing than PD-L1 in classical assays, with interesting and novel modes of actions.
iOmx's proprietary next-generation immunotherapy programs IMT-07 and IMT-18 are based on the iOTarg immune-checkpoint target discovery platform, which is designed to increase the clinical impact of immune-checkpoint therapies.